Dr. Markus Fido
Chief Executive Officer
Markus has more than 20 years of experience in pharmaceutical industry, with focus in vaccines, recombinant proteins and immune therapeutics. He has profound expertise in regulatory aspects such as third party audits, authority inspections and GMP guidelines. He has a management consulting education and holds a doctorate degree in immunology/biochemistry from the Technical University of Graz, Austria. Markus started his carrier at a Novartis “Spin off” in Vienna in 2006, he has acquired the oncology division and founded Velalabs & Meridian Biopharmaceutics. Besides serving as a CEO and formal Managing Director, Markus has also taken responsibilities as a Head of Regulatory Affairs within the Quality Operations team. Markus was previously Head Quality Control at Igeneon/Aphton Biopharma where he was responsible for all QC aspects of pre-clinical and clinical projects such as stability studies, specifications, method validation, and product release. Before that he was Group Leader of Immunology and Product Development at Biomin GmbH, Head Biochemical Control at Baxter AG and Head Quality Operations at Octapharma AG.
• 2 years Biomin AG Cell culture lab, development of immune enhancer drugs
• 6 years Baxter Inc Quality control of vaccines & coagulation factors
• 2 years Octapharma Head of Quality Operations & Quality Control (plasma products)
• 3 years Novartis AG Oncology, Cancer immune therapy, Quality + RA
• 15 years Management Buy-out (founder and CEO of 2 Biotech companies)
VelaLabs & Meridian Biopharmaceuticals
Products: Biologics, Biopharmaceuticals, Biosimilars, ATMPs, Monoclonals, Antibodies
Focus: Analytics, Quality Control, Process & Clinical Development, Regulatory Affairs
Dr. Dietmar Reusch
Characterization Analytics & Development, mAbs
Roche Diagnostics, Germany
After his study of Chemistry with focus on analytics at the University for Applied Science Reutlingen, Germany with a degree as graduate engineer in chemistry, Dietmar was engaged at TÜV Stuttgart as specialist of environmental safety. Since 1988 he is working at Roche Diagnostics. At present Dietmar is heading the Characterization Analytics department of Pharma Development at the Roche facility in Penzberg, Germany.
In 2015 he has received his PhD (Glycan analysis of therapeutic antibodies) from the University of Amsterdam. His responsibilities are the characterization and comparability of all large molecules, especially monoclonals in development and production for Roche Pharma Europe. The techniques used in his lab are including mass spectrometry, HPLC-MS, and spectroscopic methods for process development and product release. His special focus is on glycolbiology and glycan analysis with methods like HILIC/RP-UPLC after AB-labeling, HPAEC-PAD, CE and mass spectrometric based methods, including high-throughput techniques.